Evidence map›Paper›PMID 33102813›Full record

ArticleBiochemistry and biophysics reports2020

X-ray crystal structure of

Bjarni Ásgeirsson, Sigurbjörn Markússon, Sigríður S Hlynsdóttir, Ronny Helland, Jens G Hjörleifsson

Open access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Bjarni ÁsgeirssonDepartment of Biochemistry, Science Institute, University of Iceland, Dunhagi 3, 107 Reykjavik, Iceland.
Sigurbjörn MarkússonDepartment of Biochemistry, Science Institute, University of Iceland, Dunhagi 3, 107 Reykjavik, Iceland.
Sigríður S HlynsdóttirDepartment of Biochemistry, Science Institute, University of Iceland, Dunhagi 3, 107 Reykjavik, Iceland.
Ronny HellandNorStruct, Department of Chemistry, Faculty of Science and Technology, UiT - the Arctic University of Norway, NO-9037, Tromsø, Norway.
Jens G HjörleifssonDepartment of Biochemistry, Science Institute, University of Iceland, Dunhagi 3, 107 Reykjavik, Iceland.
University of Iceland · ISUiT The Arctic University of Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsCyclohexylamine inhibited four different APs. Co-crystallization with the cold-active

resultsInhibition of VAP fitted a non-competitive kinetic model (K

conclusionsThe binding of cyclohexylamine in locations at the dimeric interface and/or in the active site of APs may delay product release or reduce the rate of catalytic step(s) involving conformational changes and intersubunit communications. GENERAL SIGNIFICANCE: Cyclohexylamine is a common chemical in industries and used as a counterion in substrates for alkaline phosphatase, a clinically important and common enzyme in the biosphere.

Indexed as

Alkaline phosphataseAP, Alkaline phosphataseCyclohexylamineEnzyme inhibitorEnzymologyNon-competitiveP-nitrophenyl phosphatepNPP, p-nitrophenyl phosphateVAP, Vibrio alkaline phosphatase

Identifiers

PMID33102813
PMCPMC7569297
OpenAlexW3094069468

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.